Literature DB >> 15458562

The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.

L Hakkaart-van Roijen1, M B Hoeijenbos, E J Regeer, M ten Have, W A Nolen, C P W M Veraart, F F H Rutten.   

Abstract

OBJECTIVE: To assess the societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.
METHOD: Forty persons with a lifetime diagnosis of bipolar disorder (SCID/DSM-IV) and representative for the Dutch general population were interviewed to collect data on direct (use of medical resources) and indirect (productivity losses because of absence from work and reduced efficiency at work) costs of illness. Respondents' quality of life was also assessed. Prevalence (5.2%) of bipolar disorder was used to estimate total costs.
RESULTS: Total costs of bipolar disorder were estimated at US 1.83 billion dollars (total direct costs = US 454 million dollars; total indirect costs = US 1.37 billion dollars). Participants' quality-of-life scores were lower than those of the general population.
CONCLUSION: The societal costs form patients suffering of bipolar disorder in the Netherlands were high, especially the indirect costs because of absence from work. The quality of life of bipolar patients was lower than the general population.

Entities:  

Mesh:

Year:  2004        PMID: 15458562     DOI: 10.1111/j.1600-0447.2004.00403.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

1.  The Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2): design and methods.

Authors:  Ron de Graaf; Margreet Ten Have; Saskia van Dorsselaer
Journal:  Int J Methods Psychiatr Res       Date:  2010-09       Impact factor: 4.035

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

Review 4.  Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 5.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

6.  Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain.

Authors:  Monica Tafalla; Luis Salvador-Carulla; Jerónimo Saiz-Ruiz; Teresa Diez; Luis Cordero
Journal:  BMC Psychiatry       Date:  2010-04-28       Impact factor: 3.630

7.  The societal cost of bipolar disorder in Sweden.

Authors:  Mattias Ekman; Ola Granström; Sead Omérov; Johanna Jacob; Mikael Landén
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-06-11       Impact factor: 4.328

Review 8.  Estimating productivity costs using the friction cost approach in practice: a systematic review.

Authors:  Jesse Kigozi; Sue Jowett; Martyn Lewis; Pelham Barton; Joanna Coast
Journal:  Eur J Health Econ       Date:  2014-11-12

9.  Bipolar disorders in Australia. A population-based study of excess costs.

Authors:  Laura J Fisher; Robert D Goldney; Eleonora Dal Grande; Anne W Taylor; Graeme Hawthorne
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-11-01       Impact factor: 4.519

Review 10.  Quality of life in bipolar disorder: a review of the literature.

Authors:  Erin E Michalak; Lakshmi N Yatham; Raymond W Lam
Journal:  Health Qual Life Outcomes       Date:  2005-11-15       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.